Chronic kidney disease (CKD) has a prevalence of 10% in the general population and up to 20% in high risk groups, such as patients with diabetes[@b1]. Despite the widespread availability of renal replacement therapy in the western world, mortality of patients with end-stage renal disease (ESRD) remains high. Bacterial infection and sepsis account for up to 20% of deaths in ESRD patients and are a major cause of morbidity and hospitalization[@b2][@b3][@b4][@b5][@b6][@b7]. A defect of the immune response is thought to partly account for this observation. In ESRD the ability of neutrophils to phagocytize and kill bacteria is impaired. However, the reasons for the observed dysfunction are still not well understood. Iron overload, zinc deficiency, increased intracellular calcium, anaemia, malnutrition, time on dialysis, uremia and adverse effects of the dialysis treatment itself have been linked to neutrophil dysfunction[@b8]. On the other hand the immune system in patients with ESRD seems to be chronically activated, leading to increased neutrophil oxidative burst and increased levels of inflammatory markers (cytokines, acute-phase-proteins) which are strong predictors of mortality[@b9][@b10][@b11][@b12][@b13]. Neutrophil activation and dysfunction are probably caused by endotoxemia[@b14], a well-recognized phenomenon in ESRD. Bacterial translocation across an impaired gastrointestinal barrier might be a source for endotoxin[@b15][@b16][@b17][@b18][@b19][@b20]. Gut stunning may explain such a disruption of the gut-mucosal barrier[@b21]. In addition, if present in the blood circulation, endotoxin (as measured by surrogates such as soluble cluster of differentiation 14 (sCD14)) is also an independent predictor for mortality in ESRD[@b22][@b23].

We therefore aimed to assess the relationship between endotoxemia, neutrophil function, oxidative stress, inflammation and gut permeability in CKD patients including CKD stages 3--5, in patients with ESRD undergoing haemodialysis (HD) or peritoneal dialysis (PD) and after kidney transplantation (KT).

Results
=======

Patient characteristics
-----------------------

We enrolled 184 CKD patients (57 patients comprising CKD stages 3--5, 60 ESRD patients undergoing dialysis treatment and 67 patients after KT) and 25 healthy controls ([Fig. 1](#f1){ref-type="fig"}). Of the 57 CKD patients stage 3--5, 17 patients had an estimated glomerular filtration rate (eGFR) between 30--59 ml/min/1.73 m^2^, 29 had an eGFR between 15--29 ml/min/1.73 m^2^ and 11 had an eGFR \<15 ml/min/1.73 m^2^. Of 67 patients after KT 53 patients had an eGFR between 30--59 ml/min/1.73 m^2^ and 14 had an eGFR between 15--29 ml/min/1.73 m^2^. Of the 60 dialysis patients 32 were on HD and 28 on PD. All HD patients stayed haemodynamically stable throughout their treatment sessions. Patient groups and healthy controls were comparable in age, body mass index (BMI) and gender distribution. Patient characteristics are presented in [Table 1](#t1){ref-type="table"}.

Endotoxemia and neutrophil dysfunction in dialysis patients
-----------------------------------------------------------

In the dialysis group, endotoxin was significantly increased compared to patients with CKD stage G 3--5, patients after KT and controls (p = 0.015). The levels of lipopolysaccharide binding protein (LBP) and sCD14 were increased in all patient groups compared to controls ([Table 2](#t2){ref-type="table"}). In dialysis patients, neutrophil phagocytosis was significantly decreased to 76% of normal levels. Only a small percentage of neutrophils did not show any phagocytic activity at all. The percentage of inactive neutrophils was around 1% in healthy controls and significantly increased to 2.6% and 2.2% in dialysis patients and patients after KT (p = 0.001 and p = 0.002 respectively), whereas there was no difference compared to controls for CKD stages G3--5 patients. Age and comorbidities did not influence neutrophil phagocytosis. No relevant differences in resting burst, priming or *E. coli* stimulated burst of neutrophils were observed between CKD stages G3--5, dialysis and KT. The absolute neutrophil count was similar in patients and healthy controls. However, the neutrophil/lymphocyte ratio was significantly elevated in all patient groups compared to controls. Gut permeability as measured by diamine-oxidase (DAO) was elevated in CKD stage G3--5, dialysis patients and after KT. Neutrophil energy charge was unaltered in all groups ([Table 2](#t2){ref-type="table"}). Oxidative stress as measured by advanced oxidation protein products (AOPPs) and carbonylated proteins (CP) was significantly increased in all patient groups. Also, albumin oxidation was significantly altered as shown by a decrease in the reduced albumin fraction (human mercaptalbumin, HMA) and an increase in the oxidized fractions (human non-mercaptalbumin 1 and 2, HNA1 and HNA2; [Table 2](#t2){ref-type="table"}). The cytokine and cytokine receptor panel (Interleukin (IL)6, sIL6-receptor (sIL6 R), IL8, IL10, tumor necrosis factor (TNF)α, TNFR1, TNFR2) showed large variations but were also elevated in all patient groups compared to healthy controls ([Table 2](#t2){ref-type="table"}). C reactive protein (CRP) was not elevated in any patient group compared to controls ([Table 1](#t1){ref-type="table"}).

Differences in endotoxemia and neutrophil function with regard to dialysis modality
-----------------------------------------------------------------------------------

HD and PD patients did not differ in age, BMI, renal function or serum albumin, but HD patients had a longer dialysis vintage and a lower residual diuresis compared to PD patients ([Table 1](#t1){ref-type="table"}). Endotoxin was significantly higher and neutrophil phagocytosis was significantly lower in patients undergoing HD compared to PD ([Fig. 2A,B](#f2){ref-type="fig"}). Age and comorbidities did not influence neutrophil phagocytosis. The absolute neutrophil count, the neutrophil/lymphocyte ratio and the percentage of inactive neutrophils was similar within HD and PD. LBP, sCD14, DAO and energy charge were comparable between HD and PD patients ([Table 2](#t2){ref-type="table"}). Neutrophil resting burst was significantly higher in HD patients, whereas burst after a mild (fMLP priming) or high (*E. coli*) stimulus was significantly reduced ([Fig. 2C](#f2){ref-type="fig"}). AOPPs and CP were higher in HD than in PD patients, whereas albumin oxidation showed only a trend towards lower levels of HMA and higher levels of HNA 1 and HNA 2. Cytokine profiles showed lower IL10 but higher TNFR1 and TNFR2 levels in HD patients. CRP was elevated in HD patients compared to PD patients ([Table 2](#t2){ref-type="table"}). The type of vascular access in HD patients had no influence on endotoxemia, neutrophil function, or oxidative stress, but patients with a central venous catheter had higher CRP, sIL6R and TNFR1 levels ([Table 3](#t3){ref-type="table"}).

Influence of kidney function on endotoxemia and neutrophil function
-------------------------------------------------------------------

Within the group of CKD patients, no difference in BMI, gender or serum albumin levels was found between different CKD stages; however, CKD patients with an eGFR \>30 ml/min/1.73 m^2^ were younger than patients with an eGFR \<29 ml/min/1.73 m^2^ and \<15 ml/min/1.73 m^2^ ([Table 4](#t4){ref-type="table"}). The stage of CKD had no influence on endotoxin levels, LBP, sCD14, DAO, neutrophil phagocytosis, absolute neutrophil count, neutrophil/lymphocyte ratio, percentage of inactive neutrophils, energy charge, AOPPs and CP ([Table 4](#t4){ref-type="table"}). Neutrophil resting burst significantly increased with decreasing eGFR. In addition, HMA decreased and HNA1 and HNA2 increased significantly with the decreasing eGFR. In the cytokine panel, IL8 and TNFR1 were significantly higher in patients with an eGFR \<15 ml/min/1.73 m^2^ ([Table 4](#t4){ref-type="table"}).

The same pattern was seen in patients after KT: eGFR was not associated with changes in endotoxin, LBP, sCD14, DAO, neutrophil oxidative burst, absolute neutrophil count, neutrophil/lymphocyte ratio, percentage of inactive neutrophils, energy charge, AOPPs or CP. However, in patients after KT with an eGFR \<30 ml/min/1.73 m^2^, neutrophil phagocytosis was significantly impaired, whereas in KT patients with an eGFR \>30 ml/min/1.73 m^2^ neutrophil phagocytosis remained unaffected. Immunosuppressive therapy was not different between these groups (data not shown). Furthermore, KT patients with an eGFR \<30 ml/min/1.73 m^2^ had lower HMA and higher HNA1 and HNA2 levels as well as higher IL6, IL8, TNFR1 and TNFR2 levels.

Haemodialysis was associated with higher mortality due to infections
--------------------------------------------------------------------

In total 29 out of 184 patients died during the follow up period (median 39 months, range 30--44). All-cause mortality was lower in CKD and KT patients ((5/57 patients) and (5/67 patients)) compared to dialysis patients ((19/60 patients), p = 0.012). There was no difference in all-cause mortality between HD and PD patients ([Table 1](#t1){ref-type="table"}).

Mortality due to infections was highest in HD patients (8/12 deaths; 67%) and significantly lower in PD (1/5 deaths; 20%) patients (p = 0.022). Regarding the impact of vascular access on mortality and infections, the absolute numbers were too low to draw any meaningful statistical conclusion ([Table 3](#t3){ref-type="table"}). Endotoxin and neutrophil phagocytosis were predictive for mortality due to infection. Endotoxin levels were considerably higher in patients who later developed fatal infection compared to patients who died from other causes (15.3 (6.5, 29.3) versus 0.0 (0.0, 10.8), p = 0.025, \[EU/ml\]) and were able to predict mortality from infections ([Fig. 3](#f3){ref-type="fig"}; ROC curve: AUC = 0.827, sensitivity = 0.85, specificity = 0.75, LPS cut-off = 7.1 \[EU/ml\]). Baseline neutrophil phagocytic capacity was significantly reduced in patients who died from infections as compared to those who died from other causes (70.1 (53.9, 89.9) versus 94.5 (73.3, 145.5), (p = 0.033), \[% change of healthy controls\]).

All other studied markers did not differ between patients who died from infections as compared to patients who died from other causes.

Discussion
==========

In this cross-sectional study we demonstrate that patients on haemodialysis exhibit higher levels of endotoxemia and pronounced neutrophil dysfunction compared to PD patients, CKD stage G3--5 patients as well as patients after KT. Differences in oxidative stress, systemic inflammation, neutrophil energy status or gut permeability did not explain these findings.

In ESRD undergoing renal replacement therapy the occurrence of systemic endotoxemia is a well-recognized phenomenon. Potential sources of endotoxin in patients with ESRD are the use of non-ultrapure (contaminated) water as dialysate or bacterial translocation across an impaired mucosal gut barrier. Nowadays, due to strict regulations of dialysate composition, the risk of endotoxemia due to contaminated dialysate has been minimized[@b24]. In healthy subjects, small amounts of endotoxin regularly pass the mucosal barrier and enter the portal circulation[@b25]. The liver normally protects the systemic circulation from spill-over of bacteria and their products, mostly originating from the gut[@b26]. The liver is therefore the major site for endotoxin clearance in the body[@b25]. The reasons for the presence of high systemic levels of endotoxin in ESRD, where the liver should have a normal function, remain unclear. Possible explanations are that the degree of translocation exceeds the scavenging capacity of the liver or that the renal insufficiency attenuates the endotoxin clearance of the liver.

Systemic endotoxemia is associated with adverse outcomes in several diseases[@b27]. In ESRD the presence of sCD14 as a surrogate parameter of endotoxin load has been described as an independent predictor for mortality[@b22][@b23]. We found that increased endotoxin levels at baseline were predictive for death due to infections during follow up. Infection related mortality was lower in PD patients who share the same degree of renal impairment. Other studies have shown a higher risk for infections in PD patients[@b28] or similar overall infection rates between these two dialysis modalities, but mortality was not reported[@b29]. Since the fatality of an infection is not only influenced by the host or the dialysis modality but also by several other factors, such as access to medical care and standards in patient care, further larger studies are needed to clarify these diverging observations.

In our study neutrophil phagocytic capacity was only impaired in HD but not PD patients and normal phagocytic capacity was observed in patients after KT as long as renal function was stable. These findings suggest on the one hand, that the dialysis modality is crucial in the development of neutrophil dysfunction and on the other hand that neutrophil dysfunction is reversible after KT. PD patients have a shorter dialysis vintage and a higher residual diuresis in our study. Others have also shown that uraemia and the dialysis modality affect neutrophil phagocytosis and that impaired phagocytic capacity is reversible[@b30][@b31]. We could also link neutrophil phagocytosis to the risk of infection; a phagocytic capacity below 72% was associated with significantly higher mortality due to infections during follow up.

Since endotoxin is commonly derived from the gut, we also assessed gut permeability in our study cohort. Gut permeability, as measured by differently sized polyethylene glycols, is increased in patients with ESRD[@b16]. Furthermore bacterial overgrowth has been found in ESRD patients, which might additionally increase gut permeability and bacterial translocation[@b32][@b33]. ESRD patients often suffer from fluid volume overload, which has been shown to increase gut permeability and correlate with systemic endotoxin levels[@b34]. Over-hydration has a similar prevalence in both HD and PD[@b35]. However, in our study we only found significant endotoxemia in HD patients. From our view, over-hydration cannot be the only cause for endotoxemia observed in HD patients. For determination of gut permeability, the current gold standard is the measurement of urinary sugar recovery but this test cannot be performed in ESRD because of decreased eGFR and oftentimes minimal urine output[@b36]. Therefore, the use of surrogate biomarkers is necessary. We investigated DAO as a serum biomarker of gut permeability and LBP and sCD14 as surrogate parameters for bacterial translocation. DAO is an active intracellular molecule in the cells of the intestinal mucosa and reaches circulation when the barrier function of the gut is impaired. Thus, increased DAO levels represent increased gut permeability. DAO has been used as a biomarker for intestinal barrier dysfunction in various diseases and has been cross validated with other markers of gut permeability[@b37][@b38][@b39][@b40][@b41][@b42][@b43].

We found elevated DAO, LBP and sCD14 levels in CKD stage G3--5 patients, dialysis patients and KT patients. No differences were found in DAO, sCD14 and LBP between HD and PD. These findings support the hypothesis that increased gut permeability may be caused by intestinal hypoperfusion due to a reduction in splanchnic blood flow during HD caused by compensatory mechanisms retaining hemodynamic stability during ultrafiltration. We have recently shown that hepato-splanchnic blood flow substantially decreases during HD as a result of an active splanchnic vasoconstriction thus weakening the gut barrier, especially in diabetic subjects[@b44]. Since we collected the serum samples before the start of HD, our study was not designed to detect bacterial translocation across an ischemic ("stunned") gut barrier directly. However, our data provide further support for such a relationship as bacterial translocation might predominantly occur in the post-dialytic period[@b45]. Increased LBP and sCD14 levels in all patient groups might be due to transient or low-grade endotoxemia, which is under the detection limit of 3 EU/ml in the endotoxin assay. Central venous catheters are known sources of endotoxemia too. We did not detect differences in endotoxemia between the different types of vascular access, but the patient numbers for these subgroups were very low.

An altered gut microbiome composition could be a further driving force for endotoxemia, as discussed in a recent review[@b46] and could also contribute to the increased risk of infection. Further next-generation sequencing studies with larger patient numbers are necessary to elucidate how different stages of CKD and different renal replacement therapy modalities impact on the composition and function of the gut microbiome in renal insufficiency.

To further investigate the potential mechanism behind neutrophil dysfunction we studied the cellular energy status of isolated neutrophils. This has been associated with decreased neutrophil phagocytic capacity due to TLR4 mediated endotoxin stimulation and exhaustion of cells[@b47]. Interestingly, we did not find any alterations in energy charge of neutrophils in our patient cohort. Energy status was neither correlated with CKD stage nor with the type of renal replacement therapy. ADP and ATP were significantly reduced in all patient groups compared to controls, which makes a direct relationship to endotoxemia and neutrophil phagocytosis unlikely. Another possible explanation for the observed neutrophil dysfunction might be an interaction of neutrophils with the dialysis membrane, causing an inadequate activation of neutrophils[@b48].

Besides the above-described defect in phagocytosis, chronic activation of the innate immune system is highly prevalent in CKD[@b49]. This leads to increased levels of inflammatory markers (cytokines, acute-phase-proteins)[@b50], which are known contributors to the increased mortality in ESRD[@b51]. Both, oxidative stress and inflammation are highly prevalent in chronic kidney disease patients[@b52] and are in close interaction[@b53]. Neutrophils of patients undergoing HD show an increase in oxidative burst[@b54] which contributes to the oxidation of plasma proteins especially albumin[@b55]. Recently a misbalance in the "gut microbiome - immune system interaction" was proposed to further contribute to systemic inflammation[@b56]. We measured a panel of cytokines in serum and found that all measured parameters (IL6, sIL6R, IL8, IL10, TNFα, TNFR1 and TNFR2) were elevated in CKD patients compared to controls. We found no clear association with the degree of renal impairment. In HD patients the anti-inflammatory cytokine IL10 was lower in serum compared to PD, whereas TNFR1 and TNFR2 were nearly doubled.

Neutrophils of patients undergoing HD had a slightly, but significantly higher resting oxidative burst but their ability to increase burst through a mild or high stimulus was worse than in PD patients. We could also confirm previously published results on oxidized proteins (AOPPs, albumin) and carbonylated proteins, which were significantly elevated in all patient groups and also showed a correlation with the stage of renal insufficiency (oxidized albumin). AOPPs and CP were also significantly higher in HD versus PD patients. Oxidized albumin[@b57] and AOPPs[@b58] are not only the result of neutrophil oxidative burst damage[@b59] but can in turn again activate neutrophils. This possibly creates a vicious cycle leading to additional neutrophil dysfunction, which in turn increases the risk of infections ([Fig. 4](#f4){ref-type="fig"}).

The limitation of our study is the cross sectional, observational nature of the study which does not allow proving causality. However, the relatively large number of patients of a broad CKD-spectrum strengthens the results of this study. Another limitation is the fact, that the current gold standard for measuring intestinal permeability cannot be performed in ESRD patients, as described above. We however used different biomarkers for intestinal permeability and bacterial translocation that have been described in literature. Since we could not detect a correlation of these markers (DAO, sCD14, LBP) with renal function, we are confident that these markers reflect intestinal permeability in our patient cohort. Furthermore, measurement of endotoxin in serum samples is difficult. None of the commercially available LPS detection kits are recommended to be used for human serum samples. This paradox has been discussed before, but the Limulus Amoebocyte Assay is still in use, lacking valid alternatives[@b60][@b61]. The main problem is the presence of many inhibiting substances in serum, that can influence any of the enzymes of the Limulus Amoebocyte Assay cascade leading to decreased or false negative results[@b62][@b63]. We therefore adapted the HEK cell based assay from Invitrogen for human serum use. This assay is based on the ability of TLR4 to recognize structurally different LPS from gram-negative bacteria. To our knowledge, we are the first to describe this assay in the context of renal insufficiency. It has been previously shown that serum from uremic patients causes a down-regulation of TLR4 expression on monocytes. Therefore, we do not assume a false positive TLR4 signalling by patient sera. Additionally, cells were stimulated by serum samples in the presence of detection medium which reduced the concentration of of uremic toxins thereby minimizing the effect on HEK-cells. The absolute endotoxin levels resulting from the HEK cell based assay are significantly higher than endotoxin levels reported from the Limulus Amoebocyte Assay. In another study from our group in patients with liver cirrhosis we also observed higher endotoxin levels in relatively stable patients[@b64]. At the moment we can only speculate on the reasons. One reason might be that we used a standard curve in serum from healthy controls for this assay, whereas most users of the Limulus Amoebocyte Assay use a standard curve in water. Due to various inhibiting substances in serum, this might lead to lower absolute endotoxin levels in the Limulus Amoebocyte assay.

In summary, although endotoxemia, increased gut permeability, oxidative stress and systemic inflammation were present in all CKD patients, endotoxemia was associated with impaired neutrophil function only in HD patients. Neutrophil energy status did also not explain the differences in neutrophil function. HD patients in our study cohort not only had increased endotoxemia and impaired neutrophil function but also died more often from infections. Therefore, further studies are needed to explore the reason for endotoxemia and neutrophil dysfunction especially in HD patients. Interventions to decrease the risk for infections in ESRD are an unmet clinical need and further investigations in this field will make targeted interventions possible.

Methods
=======

We enrolled CKD patients with stages G3 to 5, patients with ESRD undergoing dialysis treatment and patients after KT at the Department of Internal Medicine, Clinical Division of Nephrology, Medical University of Graz. The Ethics Committee of the Medical University Graz (IRB00002556) approved the study protocols (23--056 ex10/11, NCT01362569). The study was conducted according to the Declaration of Helsinki and all participants gave written informed consent prior enrolment. Patients with malignancy, pregnancy, chronic inflammatory bowel disease, celiac disease, active alcohol abuse, severe organ dysfunction unrelated to renal dysfunction or patients with clinical evidence of active infection were excluded. Age and sex matched healthy controls were included in the study. These subjects had no evidence of renal disease and did not take any medication. Patients were followed-up and survival data were censored upon December 1, 2015. Causes of death were stratified into infectious causes, non-infectious causes and unknown reasons.

Blood samples were taken with sterile equipment (Vacuette, Greiner, Austria) and serum was stored in Eppendorf safe-lock tubes, 1.5 ml (Eppendorf, Vienna, Austria). Equipment was tested for endotoxin and no endotoxin was detected. Routine laboratory parameters were analysed at the Clinical Institute of Medical and Chemical Laboratory Diagnostics of the Medical University of Graz. The estimated glomerular filtration rate (eGFR) was calculated according to CKD-EPI creatinine equation (2009).

The Phagotest^®^ (Glycotope, Heidelberg, Germany) was used as directed by the manufacturer to measure phagocytosis by flow cytometric analysis using FITC-labelled opsonized *E. coli* bacteria. In brief: heparinized whole blood (100 μl) was incubated with 20 μl of FITC-labelled opsonized *E. coli* bacteria for 10 min either on ice (control) or at 37 °C. Fluorescence of surplus bacteria was quenched by addition of 100 μl of quenching solution. After 2 washing steps (3 ml wash solution) erythrocytes were lysed by addition of lysing solution (2 ml) and incubated for 20 min at room temperature. Ten minutes prior to flow cytometric measurement DNA staining solution (200 μl) was added to each sample. A forward-side scatter gate was set on neutrophils and 10,000 neutrophils were recorded. Percentage of neutrophils that showed no phagocytic activity was recorded (inactive neutrophils). The phagocytic capacity was calculated by weighing the geometric mean of fluorescence intensity (GMFI) with the percentage of low and high phagocytizing neutrophils. To overcome batch variations all values are presented as *n*-% change of healthy controls determined by the corresponding batch of bacteria. An intra-assay precision for percentage of phagocytizing cells and GMFI is given with 0.2% CV and 1.5% CV by the supplier. Quality control was carried out daily by using CS&T beads.

The Phagoburst^®^ kit (Glycotope, Heidelberg, Germany) was used as directed by the manufacturer to determine the percentage of neutrophils that produced reactive oxidants by bacterial (*E. coli*) stimulation, low stimulation (fMLP - priming) or without stimulation analysed by flow cytometry. In brief: heparinized whole blood (100 μl) was incubated with washing solution (resting burst), fMLP (N-formyl-Met-Leu-Phe; priming) or opsonized *E. coli* bacteria (bursttest) (20 μl each) for 10 min at 37 °C. Afterwards substrate solution (20 μl) were added to each tube and incubated for 10 min at 37 °C. Erythrocytes were then lysed by addition of lysing solution (2 ml) and incubated for 20 min at room temperature. Ten minutes prior to flow cytometric measurement DNA staining solution (200 μl) was added to each sample. A forward-side scatter gate was set on neutrophils and 10,000 neutrophils were recorded. Data are presented as percentage of bursting neutrophils (FITC positive). Background signal (bursting neutrophils without stimulus) was subtracted from stimulated bursting neutrophils. An intra-assay precision for percentage of oxidizing cells is given with 0.1% CV by the supplier. Flow cytometric analysis was done with an LSRII cytometer in combination with FACS Diva 6.2 software (BD Bioscience, Heidelberg, Germany). Quality control was carried out daily by using CS&T beads.

Cellular energy status in neutrophils was measured by HPLC as described in[@b65][@b66][@b67]. In brief: neutrophils were isolated by layering whole blood (5 ml) over Polymorphprep^TM^ (5 ml) (Axis-Shield, Oslo, Norway) and centrifuged at 500 g for 35 min at room temperature. Residual erythrocytes within the neutrophil phase were lysed by addition of Red Cell Lysis Buffer (2 ml) (Roche Diagnostics, Vienna Austria). Neutrophils were suspended in HBSS to the desired concentration. Neutrophils (10^6^) were deproteinized with 0.4 mol/l perchloric acid (200 μl). After centrifugation the acid extract (200 μl) was neutralized with of 2 mol/l potassium carbonate (\~15 μl, 4 °C). The supernatant obtained after centrifugation was used for HPLC analysis (injection volume: 40 μl). The pellet of the acid extract was dissolved in 0.1 mol/l sodium hydroxide (250 μl) for protein determination (BCA Protein Assay, Pierce). The HPLC analytical method for separation of the high energy phosphates has been reported previously[@b65][@b66][@b67]. Procedure in brief: Separation is performed on a Hypersil ODS column (5 μm, 250 mm × 4 mm I.D.) using a L-2200 autosampler, two L-2130 HTA pumps and a L-2450 diode array detector (all: VWR Hitachi, Austria). Detector signals (absorbance at 214 nm and 254 nm) were recorded and analysed by EZchrom Elite software (Agilent Technologies, Santa Clara, USA).

Energy charge was calculated by following formula: EC  =  (ATP + ½ ADP)/(AMP + ADP + ATP). AMP, ADP and ATP concentrations were represented as μmol/l.

The advanced oxidized protein products (AOPP) - assay was performed as described previously[@b68][@b69]. In brief, serum was depleted of ApoB-containing lipoproteins with polyetylenglycol (PEG). Precipitate was pelleted by centrifugation (10.000 × g, 30 min) and the supernatant was used for AOPP detection. Subsequently, apoB-depleted serum was mixed 0.2 mol/l citrate buffer and incubated for 2 min on a shaker. Absorbance was measured on a Nano Drop 1000 (Peqlab, Germany) spectrophotometer at 340 nm. AOPP concentrations were calculated by a chloramine-T standard curve ranging from 1 to 100 μmol/l. Carbonyl content of proteins was measured by ELISA (Immundiagnostik, Erlangen Germany) according to the manufacturers' instructions. The redox state of albumin was analysed in serum as described previously[@b70]. Samples were diluted 1:100 in sample buffer (0.1 mol/l sodium phosphate, 0.3 mol/l sodium chloride, pH 6.87) and filtered with a 0.45 μm nylon membrane (Whatman International Ltd, Maidstonem, UK). Filtrate (25 μl) of was injected and separated with an anion exchange column (Shodex Asahipak ES-502 N7C, Showa Denko, Munich, Germany) using 50 mmol/l sodium acetate, 400 mmol/l sodium sulfate, pH 4.85 as mobile phase. A gradient pump (FLUX Rheos 4000; Spectronex GmbH, Austria) applied a flow rate of 1 ml/min with an ethanol gradient reaching from 0 to 6%. The column was kept at a temperature of 35 °C. Fluorescence emission was detected by 280/340 nm with a Jasco 821FP detector (Spectronex GmbH, Vienna, Austria). Fraction quantification was done by comparing peak heights by means of EZChrom Elite chromatography software (Agilent Technologies, Santa Clara, USA) and expressed as the percent of total albumin. Thereby, reversibly oxidized albumin (human nonmercapt-albumin 1, HNA1) and irreversibly oxidized albumin (human nonmercapt-albumin 2, HNA2) were quantified.

An adapted Human embryonic kidney cells (HEK)-blue LPS detection kit (InvivoGen, San Diego, USA) was used to determine serum endotoxin levels via a cell based colorimetric assay. Endotoxin free equipment (endotoxin free glass test tubes, LAL reagent endotoxin free water (Charles Rivers, Massachusetts, USA), 6-well plates with endotoxin levels ≤0,1 EU/ml (Corning, New York, USA), low-endotoxin fetal bovine serum (Gibco, Vienna, Austria), ART Barrier tips (Fisher scientific, Vienna, Austria), combitips advanced (Biopur, Eppendorf, Vienna Austria) was used. Briefly, HEK-cells were subcultured when they reached a confluency of 80%. Cells (5×10^4^/well were incubated in 2 ml complete growth media (DMEM high glucose supplemented with 1% Pen/Strep, 10% FBS, 1× Normocin, 1× Selection mix) at 37 °C, 5% CO~2~ in a 24-well plate overnight. A five-point endotoxin standard curve (50 EU/ml to 3.125 EU/ml prepared in serum of a healthy donor) and positive controls were prepared. Growth medium was changed to detection medium (950 μl). Samples, standards and controls were added in triplicates (50 μl) and incubated overnight. Each sample was corrected for its specific alkaline phosphatase activity to avoid overestimation of endotoxin concentration using a regression model. On the next day supernatant (100 μl) was transferred in duplicates to a 96-well plate and quantified photometrically by reading the OD at 650 nm.

Soluble (s)CD14 and lipopolysaccharide binding protein (LBP) were both measured by "sandwich" ELISA (Hycult, Netherlands). A ready-to-use solid-phase "sandwich" ELISA (Immundiagnostik AG, Bensheim, Germany) was used to detect diamine-oxidase (DAO) in serum samples. All ELISA Kits have been performed exactly as suggested by the manufacturer.

Interleukins (IL6, IL8, IL10) as well as tumour necrosis factor- α (TNF-α), and soluble TNF receptor (sTNFR) -1 were analysed by FlowCytomix (eBioscience, Vienna Austria). Both, soluble IL6-receptor (sIL6R) and sTNFR2 were determined by "sandwich" ELISA (eBioscience, Vienna, Austria). All Kits have been performed exactly as suggested by the manufacturer.

Statistics
----------

All statistical analyses were performed using SPSS version 23.0 (SPSS Inc., Chicago, IL) and GraphPad Prism version 5.0 for visualisations. Comparison of two independent groups with normal distributed parameters was tested for homogeneity (Levene's test) and accordingly assessed by T-test or Welch; three or more groups were compared by ANOVA using Tukey's or Games-Howell's correction. For parameters, which were not normally distributed, non-parametric tests were used (Mann Whitney U test, or Kruskal-Wallis and Wilcoxon signed rank test). Two-tailed Pearson or Spearman tests were used for metrical data correlation. Nominal and ordinal scaled data comparison was assessed by Chi-square test using Pearson or Fisher's Exact test. Survival analysis were performed by Kaplan Meier curves and assessed by Log-Rank (Mantel-Cox). ROC curve and Youden index were used to define a cut-off value. All statistical tests were 2-sided, and p-values \< 0.05 were considered statistically significant. Data are presented as median and quartiles (Q~1~, Q~3~).
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ROC curves (left) were used to determine the cut-off level of endotoxin (**A**) and phagocytosis (PI) (**C**). Both Kaplan Maier curves (right) show that patients with increased endotoxin levels (LPS) (**B**) or reduced phagocytosis (**D**) die more often from infection.](srep34534-f3){#f3}

![The hypothesis of a vicious cycle in chronic renal disease.\
The risk of infection increases as result of a disturbed gut barrier and endotoxemia leading to neutrophil dysfunction.](srep34534-f4){#f4}

###### Patient characteristics.

                                                  CKD stage 3--5   Dialysis (HD + PD)   Dialysis subgroups    KT    Healthy controls                                                                                                                                                                                                                           
  ---------------------------------------------- ---------------- -------------------- -------------------- ------ ------------------ --------------------------------- ------ -------------- ----------------------------------------------------------- ------- ------------- ------------------------------ ------ -------------- --- ------ -------------- --------------------------------
  Age \[years\]                                         61              (50, 68)                              56        (42, 68)                                          56      (44, 70)                                                                  54      (35, 66)                                     56      (47, 66)          50      (44, 59)                    
  Sex \[male\], % (n)                                   63               \(36\)                               62         \(37\)                                           53       \(17\)                                                                   71       \(20\)                                      63       \(42\)           48       \(12\)                     
  BMI \[kg/m^2^\]                                      27.7           (24.7, 34.8)                           26.3     (23.4, 30.4)                                       24,6   (22.6, 30.1)                                                               27, 8   (24, 30.4)                                   25.3   (23.0, 28.6)   c   26,7   (24.5, 27.8)                  
  Dialysis vintage \[months\]                                             ---                                 41        (21, 89)                                          70     (27, 154)                    [§](#t1-fn2){ref-type="fn"}                   29      (18, 44)                                     61     (12, 138)         ---                                  
  Residual diuresis \[ml\]                                                                                   850       (0, 3800)                                          50      (0, 563)                    [§](#t1-fn2){ref-type="fn"}                  1225    (638, 1850)                                                                                                 
  **Medication % (n)**                                                                                                                                                                                                                                                                                                                                         
  Sevelamer                                             4                \(2\)                                52         \(31\)                                           50       \(16\)                                                                   54       \(15\)                                     ---                                  ---                       
  Immunosuppression                                     11               \(6\)                                5          \(3\)                                            9        \(3\)                                                                     0        \(0\)                                     100       \(67\)                     ---                       
  **Aetiology of renal disease % (n)**                                                                                                                                                                                                                                                                                                                         
  Immunological[‡](#t1-fn4){ref-type="fn"}              32               \(18\)                               27         \(16\)                                           19       \(6\)                                                                    36       \(10\)                                      45       \(30\)                     ---                       
  Non-immunological[‡](#t1-fn4){ref-type="fn"}          63               \(36\)                               40         \(24\)                                           44       \(14\)                                                                   36       \(10\)                                      31       \(21\)                     ---                       
  other                                                 5                \(3\)                                33         \(20\)                                           38       \(12\)                                                                   29        \(8\)                                      24       \(16\)                     ---                       
  **Comorbidities**                                                                                                                                                                                                                                                                                                                                            
  Charlson Comorbidity Index                            5                (2, 9)                               4         (2, 12)                                           4       (2, 12)                                                                    4       (2, 12)                                     4       (2, 10)                     ---                       
  Cardiovascular diseases, % (n)                        69               \(39\)                               50         \(30\)                                           59       \(19\)                                                                   39       \(11\)                                      64       \(43\)                     ---                       
  Diabetes, % (n)                                       35               \(20\)                               28         \(17\)                                           38       \(12\)                                                                   18        \(5\)                                      25       \(17\)                     ---                       
  **Laboratory parameters**                                                                                                                                                                                                                                                                                                                                    
  eGFR \[ml/min/1,73 m^2^\]                            23.2           (16.0, 31.1)              a            5.7       (4.8, 8.0)                     b                  5,8     (5.0, 7.4)                  [\*](#t1-fn2){ref-type="fn"}                   5,7    (4.5, 8.9)    [\*](#t1-fn2){ref-type="fn"}   43.5   (31.0, 58.0)   c   82.0   (61.2, 93.7)   [\*\*](#t1-fn2){ref-type="fn"}
  Albumin \[g/dl\]                                     4.2             (3.9, 4.4)               a            4.0       (3.7, 4.2)                     b                   4      (3.7, 4.3)                  [\*](#t1-fn2){ref-type="fn"}                   3,9    (3.7, 4.1)    [\*](#t1-fn2){ref-type="fn"}   4.4     (4.2, 4.6)    c   4.7     (4.6, 5.0)    [\*\*](#t1-fn2){ref-type="fn"}
  Creatinine \[mg/dl\]                                 2.5             (2.0, 3.6)               a            8.1      (6.7, 10.0)                     b                   8      (6.7, 9.8)                  [\*](#t1-fn2){ref-type="fn"}                   8,4    (6.6, 11.4)   [\*](#t1-fn2){ref-type="fn"}   1.6     (1.2, 2.0)    c   0.9     (0.8, 1.0)    [\*\*](#t1-fn2){ref-type="fn"}
  Urea \[mg/dl\]                                        93             (66, 131)                              98       (84, 113)                      b                   98     (77, 109)                   [\*](#t1-fn2){ref-type="fn"}                   99      (89, 125)    [\*](#t1-fn2){ref-type="fn"}    59      (47, 73)     c    32      (27, 36)     [\*\*](#t1-fn2){ref-type="fn"}
  Phosphate \[mmol/l\]                                 1.2             (1.0, 1.3)               a            1.6       (1.3, 1.9)      [\*](#t1-fn2){ref-type="fn"}, b   1,7     (1.2, 2.0)                  [\*](#t1-fn2){ref-type="fn"}                   1,5    (1.3, 1.9)    [\*](#t1-fn2){ref-type="fn"}   0.9     (0.8, 1.1)    c   1.0     (0.8, 1.1)                   
  CRP \[mg/l\]                                         2.4             (1.3, 6.5)                            3.0       (0.9, 9.1)                                        7.4    (1.0, 13.6)    [\*](#t1-fn2){ref-type="fn"}, [§](#t1-fn2){ref-type="fn"}    1.8    (0.8, 4.1)                                   2.3     (0.9, 4.8)        1.6     (0.6, 2.4)                   
  Neutrophil count \[G/l\]                             4.2             (3.5, 4.5)                            4.4       (3.3, 6.0)                                         4      (3.1, 6.0)                                                                 4,4    (3.5, 5.7)                                   4.2     (3.2, 5.7)        4.2     (3.3, 4.9)                   
  Neutrophil/lymphocyte ratio                          3.1             (2.1, 4.1)                            2.9       (1.9, 4.5)                                        3,2     (2.0, 5.4)                  [\*](#t1-fn2){ref-type="fn"}                   2,6    (1.8, 4.0)    [\*](#t1-fn2){ref-type="fn"}   3.3     (2.2, 4.7)        1.8     (1.5, 2.4)    [\*\*](#t1-fn2){ref-type="fn"}
  **Deceased % (n)**                                                                                                                                                                                                                                                                                                                                           
  All-cause mortality                                   9                \(5\)                  a             32         \(19\)                       b                   38       \(12\)                                                                   25        \(7\)                                      8        \(5\)                      ---                       
  Infectious-cause mortality                           1.8               \(1\)                  a             15         \(9\)                        b                   25       \(8\)                      [§](#t1-fn2){ref-type="fn"}                   3.6       \(1\)                                      5        \(3\)                      ---                       

CKD chronic kidney disease, HD haemodialysis, PD peritoneal dialysis, KT after kidney transplantation, BMI Body mass index, eGFR estimated glomerular filtration rate, CRP C-reactive protein.

a, b, c significant difference to another patient group (a: CKD to Dialysis, b: Dialysis to KT, c: KT to CKD), ^\*^significant difference to healthy controls, ^\*\*^all patient groups (CKD, Dialysis, KT) differ significantly from healthy controls, **Dialysis subgroups:** ^§^significant difference between HD and PD patients, ^\*^significant difference to healthy controls.

-data not available, data is shown as median (Q1, Q3) unless stated otherwise.

^‡^Immunological: glomerulonephritis, Non-immunological: cystic kidneys, diabetic-/ vascular nephropathy.

###### Endotoxin, gut permeability, neutrophil function oxidative stress and inflammation in ESRD.

                                                          CKD stage 3--5      Dialysis            Dialysis subgroups           KT     Healthy controls                                                                                                                                                                                                                                                             
  ------------------------------------------------------ ---------------- ---------------- --------------------------------- ------- ------------------ --------------------------------- ------ -------------- ----------------------------------------------------------- ------ --------------- ------------------------------ ------- ---------------- ------------------------------ ------- ---------------- --------------------------------
  **Endotoxemia and gut permeability**                                                                                                                                                                                                                                                                                                                                                                             
  Endotoxin \[EU/ml\]                                          1.3           (0.0, 5.7)                                        5.4      (0.0, 13.3)       [\*](#t2-fn2){ref-type="fn"}     8.9    (0.0, 15.6)    [\*](#t2-fn2){ref-type="fn"}, [§](#t2-fn2){ref-type="fn"}    0      (0.0, 7.0)                                     1.0      (0.0, 7.0)                                     0.0      (0.0, 1.8)                    
  LBP \[μg/ml\]                                                34.8         (25.7, 44.0)                                      28.3      (21.4, 40.5)                                       28.3   (22.7, 49.0)                 [\*](#t2-fn2){ref-type="fn"}                  28.3   (18.6, 37.3)    [\*](#t2-fn2){ref-type="fn"}   27.0     (19.7, 37.8)                                   14.3     (12.7, 20.6)    [\*\*](#t2-fn2){ref-type="fn"}
  sCD14 \[μg/ml\]                                              2.7           (2.2, 4.1)                                        2.9       (2.5, 3.9)                     b                  3.3     (2.6, 4.2)                  [\*](#t2-fn2){ref-type="fn"}                  2.8     (2.5, 3.2)     [\*](#t2-fn2){ref-type="fn"}    2.3      (1.9, 2.8)                                     1.7      (1.3, 2.3)     [\*\*](#t2-fn2){ref-type="fn"}
  DAO \[ng/ml\]                                                33.1         (26.3, 44.4)                                      26.3      (20.6, 37.5)                                       31.9   (21.9, 44.8)                 [\*](#t2-fn2){ref-type="fn"}                  25.6   (20.0, 30.0)                                   31.9     (22.5, 39.4)                                   19.7     (14.5, 34.4)    [\*\*](#t2-fn2){ref-type="fn"}
  **Neutrophil function**                                                                                                                                                                                                                                                                                                                                                                                          
  Phagocytosis \[% change to healthy controls\]               103.9        (83.6, 166.5)                   a                  76.2     (61.0, 101.2)     [\*](#t2-fn2){ref-type="fn"}, b   70.6   (49.6, 87.1)   [\*](#t2-fn2){ref-type="fn"}, [§](#t2-fn2){ref-type="fn"}   92.2   (65.9, 135.3)                                  100.8   (76.9, 152.1)                                   100.0   (83.5, 129.2)                   
  Inactive neutrophils \[%\]                                   1.60          (1.0, 4.9)                                        2.6       (1.5, 5.9)       [\*](#t2-fn2){ref-type="fn"}     2.6     (1.4, 4.3)                  [\*](#t2-fn2){ref-type="fn"}                  1.8     (1.2, 5.5)     [\*](#t2-fn2){ref-type="fn"}    2.2      (1.4, 4.4)     [\*](#t2-fn2){ref-type="fn"}    1.1      (0.5, 1.6)                    
  Energy charge                                                0.79         (0.75, 0.84)                                      0.81      (0.77, 0.85)                                       0.80   (0.76, 0.84)                                                               0.82   (0.78, 0.88)                                   0.81     (0.77, 0.86)                                   0.82     (0.77, 0.85)                   
  Resting burst (no stimulus) \[%\]                            3.1           (2.4, 4.4)                                        3.1       (2.5, 3.9)                                        3.6     (2.7, 4.6)    [\*](#t2-fn2){ref-type="fn"}, [§](#t2-fn2){ref-type="fn"}   2.8     (2.3, 3.4)                                     3.7      (2.7, 5.4)     [\*](#t2-fn2){ref-type="fn"}    2.8      (2.3, 3.2)                    
  Priming (low stimulus by fMLP) \[%\]                         1.4           (0.0, 5.4)                                        3.3       (1.0, 6.0)                                        1.6     (0.6, 3.5)                   [§](#t2-fn2){ref-type="fn"}                  4.2     (2.9, 7.3)                                     2.9      (1.0, 6.0)                                     2.7      (1.5, 4.6)                    
  Burst (bacterial stimulus by *E. coli*) \[%\]                93.7         (90.7, 95.7)                                      94.1      (89.6, 95.4)                                       90.9   (85.7, 94.6)   [\*](#t2-fn2){ref-type="fn"}, [§](#t2-fn2){ref-type="fn"}    95    (93.9, 95.9)    [\*](#t2-fn2){ref-type="fn"}   92.6     (86.6, 95.6)                                   96.2     (95.4, 97.0)    [\*\*](#t2-fn2){ref-type="fn"}
  **Oxidative stress**                                                                                                                                                                                                                                                                                                                                                                                             
  AOPP \[μmol/l\]                                              54.9         (33.5, 74.1)                   a                  73.6      (55.5, 98.6)                    b                   91     (63, 114)     [\*](#t2-fn2){ref-type="fn"}, [§](#t2-fn2){ref-type="fn"}    67      (51, 80)      [\*](#t2-fn2){ref-type="fn"}   53.5     (35.2,70.2)                                    30.7     (26.4, 36.8)    [\*\*](#t2-fn2){ref-type="fn"}
  HMA \[%\]                                                    57.4         (52.6, 63.9)                                      61.3      (56.4, 67.8)                                       59.1   (54.1, 67.8)                 [\*](#t2-fn2){ref-type="fn"}                  64.3   (60.2, 67.9)    [\*](#t2-fn2){ref-type="fn"}   63.3     (59.4, 67.8)                 c                 73.6     (69.6, 76.3)    [\*\*](#t2-fn2){ref-type="fn"}
  HNA1 \[%\]                                                    40          (33.4, 44.7)                   a                  35.2      (28.7, 40.2)                                       38.0   (28.7, 42.6)                 [\*](#t2-fn2){ref-type="fn"}                  31.9   (28.6, 37.1)    [\*](#t2-fn2){ref-type="fn"}   33.5     (29.8, 37.2)                 c                 25.0     (21.4, 28.0)    [\*\*](#t2-fn2){ref-type="fn"}
  HNA2 \[%\]                                                   2.1           (1.9, 2.7)                    a                   3.3       (2.8, 3.9)       [\*](#t2-fn2){ref-type="fn"}     3.2     (2.8, 4.0)                  [\*](#t2-fn2){ref-type="fn"}                  3.4     (2.7, 3.9)     [\*](#t2-fn2){ref-type="fn"}    2.9      (2.3, 3.8)     [\*](#t2-fn2){ref-type="fn"}    2.4      (1.8, 2.8)                    
  CP \[pmol/mg protein\]                                      206.7        (190.4, 223.0)                                     199.3    (173.3, 223.9)                                      207     (182, 235)    [\*](#t2-fn2){ref-type="fn"}, [§](#t2-fn2){ref-type="fn"}   183     (170, 208)                                    206.9   (186.1, 224.4)                c                 175.1   (143.0, 194.0)   [\*\*](#t2-fn2){ref-type="fn"}
  **Inflammation**                                                                                                                                                                                                                                                                                                                                                                                                 
  Ferritin \[ng/ml\]                                           126           (56, 219)                     a                   237       (128, 433)                     b                  349     (222, 519)    [\*](#t2-fn2){ref-type="fn"},[§](#t2-fn2){ref-type="fn"}    163      (94, 234)                                     126      (68, 254)                                      135      (71, 286)                     
  Transferrin saturation \[%\]                                  23            (18, 33)                                         26         (20, 31)                                          27      (19, 32)                                                                  25      (20, 30)                                      26        (20, 33)                                      28        (22, 38)                     
  **Cytokine \[pg/ml\] and -receptor \[ng/ml\] panel**                                                                                                                                                                                                                                                                                                                                                             
  IL6                                                          2.0           (0.9, 3.7)                                        3.8       (2.1, 6.8)                     b                  4.5     (1.8, 9.9)                  [\*](#t2-fn2){ref-type="fn"}                  3.0     (2.1, 4.8)     [\*](#t2-fn2){ref-type="fn"}    1.8      (0.5, 3.3)                                     0.0      (0.0, 0.1)     [\*\*](#t2-fn2){ref-type="fn"}
  sIL6R                                                        250           (225, 325)     [\*](#t2-fn2){ref-type="fn"}, a    225       (175, 275)       [\*](#t2-fn2){ref-type="fn"}     225     (175, 275)                                                                225     (181, 275)     [\*](#t2-fn2){ref-type="fn"}    225      (175, 275)                  c                  185      (155, 225)                    
  IL8                                                          15.2         (6.8, 25.7)                                       10.8      (5.7, 20.1)                                        13.7   (5.5, 26.0)                  [\*](#t2-fn2){ref-type="fn"}                  10.6    (7.3, 12.4)    [\*](#t2-fn2){ref-type="fn"}   13.4     (7.2, 20.6)                                     1.3      (0.0, 2.4)     [\*\*](#t2-fn2){ref-type="fn"}
  IL10                                                         2.1           (0.3, 4.7)                                        3.4       (1.5, 7.6)                                        2.5     (0.0, 5.0)    [\*](#t2-fn2){ref-type="fn"}, [§](#t2-fn2){ref-type="fn"}   6.1     (2.4, 10.6)    [\*](#t2-fn2){ref-type="fn"}    1.9      (0.0, 5.6)                                     0.0      (0.0, 0.0)     [\*\*](#t2-fn2){ref-type="fn"}
  TNFα                                                         0.9           (0.0, 5.5)                                        1.0       (0.0, 5.0)                                        0.0     (0.0, 4.6)                                                                2.0     (0.0, 5.5)     [\*](#t2-fn2){ref-type="fn"}    0.0      (0.0, 5.7)                                     0.0      (0.0, 0.0)     [\*\*](#t2-fn2){ref-type="fn"}
  sTNFR1                                                       7.9          (5.2, 11.7)                    a                  25.1      (16.4, 33.7)                    b                  28.9   (22.4, 39.6)                 [\*](#t2-fn2){ref-type="fn"}                  18.3   (12.4, 27.8)    [\*](#t2-fn2){ref-type="fn"}    4.5      (2.6, 6.2)                  c                  1.0      (0.7, 1.3)     [\*\*](#t2-fn2){ref-type="fn"}
  sTNFR2                                                        14            (11, 18)                                         19         (11, 25)       [\*](#t2-fn2){ref-type="fn"}, b    24      (20, 29)     [\*](#t2-fn2){ref-type="fn"}, [§](#t2-fn2){ref-type="fn"}    11       (8, 16)                                      10        (7, 15)                                        5        (4, 22)                      

CKD chronic kidney disease, HD haemodialysis, PD peritoneal dialysis, KT kidney transplantation, LBP LPS binding protein, sCD14 soluble CD14, DAO diamine oxidase, AOPP advanced oxidation protein products, HMA human mercaptalbumin, HNA human non-mercaptalbumin, CP carbonylated proteins, IL interleukin, sIL6R soluble interleukin 6 receptor, TNFα Tumour necrosis factor α, sTNFR1/2 soluble TNF receptor ½.

a, b, c significant difference to another patient group (a: CKD to Dialysis, b: Dialysis to KT, c: KT to CKD), ^\*^significant difference to healthy controls, ^\*\*^all patient groups (CKD, Dialysis, KT) differ significantly from healthy controls, **Dialysis subgroups:** ^§^significant difference between HD and PD patients, ^\*^significant difference to healthy controls, -data not available, data is shown as median (Q1, Q3) unless stated otherwise.

###### Influence of vascular access in patients undergoing haemodialysis.

                                                   Types of vascular access                                                                                                                           
  ----------------------------------------------- -------------------------- -------------- ----------------------------- ------ --------------- ----------------------------- ------ --------------- ------
  Vascular access % (n)                                       53                 \(17\)                                     19        \(6\)                                      28        \(9\)       n.s.
  endotoxin \[EU/ml\]                                        7.4              (0.0, 13.6)                                  8.9     (0.0, 15.2)                                  10.8    (3.5, 27.8)    n.s.
  sCD14 \[μg/ml\]                                            3.4               (2.5, 4.9)                                  2.9     (2.5, 3.6)                                   3.6     (2,8, 4.2)     n.s.
  LBP \[μg/ml\]                                              28.2             (21.1, 52.4)                                 45.5   (20.4, 65.4)                                  26.6   (23.3, 36.1)    n.s.
  DAO \[ng/ml\]                                              28.8             (19.4, 38.1)                                 26.3   (24.2, 47.0)                                  36.9   (26.9, 55.0)    n.s.
  phagocytosis \[% change to healthy controls\]              61.6             (46.9, 92.7)                                 87.2   (72.7, 111.9)                                 87.2   (72.7, 111.9)   n.s.
  TNFα \[pg/ml\]                                             0.7               (0.0, 5.4)                                  3.6     (0.4, 13.5)    [§](#t3-fn1){ref-type="fn"}   0.0     (0.0, 0.0)       
  sIL6R \[ng/ml\]                                            225               (175, 263)                                  162     (150, 238)     [§](#t3-fn1){ref-type="fn"}   350     (193, 413)       
  sTNFR1 \[ng/ml\]                                           28.0             (22.6, 31.7)                                 21.6   (13.5, 29.3)    [§](#t3-fn1){ref-type="fn"}   44.1   (33.0, 45.6)      
  CRP \[mg/l\]                                               1.6               (0.6, 9.7)    [§](#t3-fn1){ref-type="fn"}   8.0     (1.3, 25.2)                                  9.5     (8.1, 36.0)      
  **Mortality % (n)**                                                                                                                                                                                 
  All causes                                                  34                 \(4\)                                      33        \(2\)                                      67        \(6\)       n.s.
  Infections                                                  24                 \(4\)                                      33        \(2\)                                      22        \(2\)       n.s.

^§^Significant difference to patients with catheter, n.s. not significant, Median (Q~1~, Q~3~) unless stated otherwise.

AVF arteriovenous fistula, AVG arteriovenous graft, CAT catheter, sCD14 soluble CD14, LBP LPS binding protein, DAO diamine-oxidase, sIL6R soluble interleukin 6 receptor, sTNFR1 soluble TNF receptor 1.

###### Chronic kidney disease patients with different stages of renal insufficiency (eGFR).

                                                          eGFR \[ml/min/1,73 m^2^\]                                                                             
  ------------------------------------------------------ --------------------------- ---------------- --- ------- ---------------- --- ------- ---------------- --------------------------------
  Age \[years\]                                                      55                  (41, 62)           62        (49, 71)           64        (53, 72)                    c
  Sex \[male\], % (n)                                                71                   \(12\)            55         \(16\)            72         \(8\)                       
  BMI \[kg/m^2^\]                                                   26.1               (23.9, 30.5)        30.5     (24,8, 37.5)        27.5     (24.7, 31.7)                   
  **Medication % (n)**                                                                                                                                          
  Sevelamer                                                           0                   \(0\)              3         \(1\)              9         \(1\)                       
  Immunosuppression                                                  18                   \(3\)             10         \(3\)              0         \(0\)                       
  **Aetiology of renal disease % (n)**                                                                                                                          
  Immunological [‡](#t4-fn3){ref-type="fn"}                          41                   \(7\)             28         \(8\)             27         \(3\)                       
  Non-immunological [‡](#t4-fn3){ref-type="fn"}                      59                   \(10\)            64         \(18\)            72         \(8\)                       
  other                                                               0                   \(0\)             10         \(3\)              0         \(0\)                       
  **Comorbidities % (n)**                                                                                                                                       
  Charlson Comorbidity Index                                          0                   (0, 3)       a     4         (0, 5)             0         (0, 4)                      
  Cardiovascular diseases                                            59                   \(10\)            66         \(19\)            91         \(10\)                      
  Diabetes                                                           24                   \(4\)             45         \(13\)            27         \(3\)                       
  **Laboratory parameters**                                                                                                                                     
  eGFR \[ml/min/1,73 m^2^\]                                         41.6               (33.3, 52.2)        21.2     (18.5, 26.4)        13.0     (9.5, 14.2)     [\*\*](#t4-fn1){ref-type="fn"}
  Albumin \[g/dl\]                                                   4.2                (3.8, 4.4)          4.2      (4.0, 4.4)          4.1      (3.9, 4.2)                    
  Creatinine \[mg/dl\]                                               1.7                (1.4, 2.1)          2.6      (2.2, 3.4)          4.7      (3.7, 5.4)     [\*\*](#t4-fn1){ref-type="fn"}
  Urea \[mg/dl\]                                                     57                  (47, 80)           96       (82, 128)           144      (120, 153)     [\*\*](#t4-fn1){ref-type="fn"}
  Phosphate \[mmol/l\]                                               1.1                (0.9, 1.3)          1.1      (0.9, 1.2)     b    1.5      (1.2, 1.8)                   c
  CRP \[mg/l\]                                                       1.7                (0.6, 6.2)          2.4      (1.4, 6.3)          5.0     (1.6, 13.9)                    
  Ferritin \[ng/ml\]                                                 150                (76, 229)           83       (47, 181)           184      (90, 222)                     
  Transferrin saturation \[%\]                                      29.0                 (19, 34)          22.0       (19, 32)          21.0       (15, 32)                     
  Neutrophil count \[G/l\]                                           4.1                (3.2, 5.5)          4.8      (3.8, 5.5)          3.9      (3.7, 4.6)                    
  Neutrophil/lymphocyte ratio                                        2.7                (2.1, 3.6)          3.3      (2.0, 4.1)          3.2      (2.4, 5.4)                    
  **Endotoxemia and gut permeability**                                                                                                                          
  Endotoxin \[EU/ml\]                                                1.4                (0.0, 4.9)          0.0      (0.0, 7.4)          3.0      (0.0, 6.2)                    
  LBP \[μg/ml\]                                                     24.8               (17.6, 36.7)        34.8     (29.8, 45.2)        38.1     (26.6, 48.8)                   
  sCD14 \[μg/ml\]                                                    2.2                (1.9, 3.2)          3.0      (2.2, 5.5)          2.5      (2.3, 3.4)                    
  DAO \[ng/ml\]                                                     39.4               (27.5, 49.7)        31.9     (24.2, 41.3)        32.5     (26.7, 45.3)                   
  **Neutrophil function**                                                                                                                                       
  Phagocytosis \[% change to healthy controls\]                     134.3             (98.3, 189.3)        92.6    (83.1, 125.0)        107.3   (63.0, 167.3)                   
  Inactive neutrophils \[%\]                                         1.9                (0.8, 7.2)          1.5      (1.1, 5.4)          1.6      (0.9, 3.6)                    
  Energy charge                                                     0.84               (0.77, 0.87)        0.77     (0.74, 0.83)        0.79     (0.76. 0.87)                   
  Resting burst (no stimulus) \[%\]                                  2.4                (1.8, 2.9)     a    3.4      (1.8, 2.9)          4.1      (3.1, 5.2)                   c
  Priming (low stimulus by fMLP) \[%\]                               0.7                (0.0, 4.7)          2.7      (0.7, 6.6)          0.1      (0.0, 3.6)                    
  Burst (bacterial stimulus by *E. coli*) \[%\]                     94.4               (90.7, 96.1)        94.4     (92.4, 95.9)        92.0     (88.7, 93.4)                   
  **Oxidative stress**                                                                                                                                          
  AOPP \[μmol/l\]                                                   43.7               (31.8, 57.3)        57.3     (32.7, 73.1)        73.8    (51.6, 107.5)                   
  HMA \[%\]                                                         65.1               (60.1, 67.7)    a   56.5     (51.7, 60.7)        52.1     (47.8, 56.0)                  c
  HNA1 \[%\]                                                        33.2               (30.7, 38.2)    a   41.7     (37.5, 45.9)        44.7     (38.7, 48.2)                  c
  HNA2 \[%\]                                                         2.0                (1.5, 2.2)          2.1      (1.9, 2.5)     b    3.0      (2.9, 4.1)                   c
  CP \[pmol/mg protein\]                                            197.9             (186.9, 220.8)       204.6   (183.0, 219.2)       214.2   (198.1, 229.3)                  
  **Cytokine \[pg/ml\] and -receptor \[ng/ml\] panel**                                                                                                          
  IL6                                                                1.6                (0.6, 2.3)          2.1      (0.8, 3.5)          2.4      (1.3, 8.8)                    
  sIL6 R                                                             300                (238, 325)          250      (225, 338)          250      (200, 250)                    
  IL8                                                               12.1               (4.9, 25.1)          9.9     (5.6, 21.0)     b   27.9     (15.2, 58.9)                  c
  IL10                                                               0.8                (0.0, 4.8)          3.0      (1.2, 4.6)          2.1      (0.0, 5.9)                    
  TNFα                                                               1.4                (0.0, 5.7)          2.0      (0.0, 5.7)          0.0      (0.0, 4.4)                    
  sTNFR1                                                             4.3                (2.4, 6.8)          8.4     (6.2, 11.7)         12.6     (10.3, 16.4)    [\*\*](#t4-fn1){ref-type="fn"}
  sTNFR2                                                             10                  (8, 21)            13        (11, 17)           18        (12, 19)                     

a, b, c significant difference to another patient group (a: eGFR 30--59 to eGFR 15--29, b: eGFR 15--29 to eGFR \<15, c: eGFR \<15 to eGFR 30--59), ^\*\*^all patient groups differ significantly from each other, - data not available, data is shown as median (Q1, Q3) unless stated otherwise.

LBP LPS binding protein, sCD14 soluble CD14, DAO Diamine-Oxidase, AOPP Advance Oxidation Protein Products, HMA human mercaptalbumin, HNA human non-mercaptalbumin, CP Carbonylated proteins, IL Interleukin, sIL6R soluble Interleukin 6 receptor, TNFα Tumor necrosis factor α, sTNFR1/2 soluble TNF receptor 1/2.

^‡^Immunological: glomerulonephritis, Non-immunological: cystic kidneys, diabetic-/ vascular nephropathy.

[^1]: These authors contributed equally to this work.
